

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**Annual Report and Audited Financial Statements**  
**for the financial year ended 31 December 2024**

**KSi Faulkner Orr Limited**  
**10 Lower Mount Street**  
**Dublin 2**  
**Ireland**

**Company Number: 550867**

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**CONTENTS**

	<b>Page</b>
Reference and Administrative Information	3
Directors' Annual Report	4 - 6
Directors' Responsibilities Statement	7
Independent Auditor's Report	8 - 9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12 - 21
Supplementary Information	23 - 27

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**REFERENCE AND ADMINISTRATIVE INFORMATION**

<b>Directors</b>	Declan Meenagh Cora Rafter Martin Hoey (Appointed 28 March 2024) Rachel Kelly (Resigned 28 March 2024)
<b>Company Secretary</b>	Lorna Regan
<b>Company Registration Number</b>	550867
<b>Registered Office</b>	27 Annamoe Terrace Cabra Dublin 7 Ireland
<b>Auditors</b>	KSi Faulkner Orr Limited 10 Lower Mount Street Dublin 2 Ireland
<b>Principal Bankers</b>	Allied Irish Banks, 53 Main Street, Finglas, Dublin 11.

# **Finglas Cabra Drugs and Alcohol Task Force CLG**

## **DIRECTORS' ANNUAL REPORT**

for the financial year ended 31 December 2024

The directors present their Directors' Annual Report, combining the Directors' Report and Trustees' Report, and the audited financial statements for the financial year ended 31 December 2024.

The financial statements are prepared in accordance with the Companies Act 2014, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

The Directors' Report contains the information required to be provided in the Directors' Annual Report under the Statement of Recommended Practice (SORP) guidelines. The directors of the company are also company trustees for the purpose of company law and under the company's constitution are known as members of the board of trustees.

In this report the directors of Finglas Cabra Drugs and Alcohol Task Force CLG present a summary of its purpose, governance, activities, achievements and finances for the financial year 2024.

### **Principal Activity**

The principal activity of the company is the coordination and delivery of evidence-informed drug and alcohol programmes through a local inter-agency Task Force model. Operating in the Finglas and Cabra areas, the company works collaboratively with statutory services, community groups, families, and local representatives to build resilience at individual, family, and community levels in response to problem drug use. By fostering social capital and facilitating a two-way flow of information between community members and decision-makers, the company supports communities in developing local solutions and enhancing their capacity to respond to adversity. This work aligns with the objectives of the National Drug Strategy, which recognises the key role of Drug and Alcohol Task Forces in supporting recovery and reducing harm.

### **Mission, Objectives and Strategy**

#### **Objectives**

The company's objectives and principal activities are the development and implementation of community based drug and alcohol related services.

### **Structure, Governance and Management**

#### **Structure**

The organisation is a company limited by guarantee, incorporated on 10 October 2014 under the Companies Act 2014. The company does not have a share capital and consequently the liability of members is limited, subject to an undertaking by each member to contribute to the net assets or liabilities of the company on winding up such amounts as may be required not exceeding two Euros (€2).

The company was established under a Memorandum of Association which established the objects and powers of the company and is governed under its Articles of Association and managed by Board of Directors.

#### **Governance**

The company has three directors who meet on a regular basis and are responsible for the strategic direction of the company. At these meetings, the board of directors are provided with the key performance and risk indicators. The company is run on a day to day basis by a manager who is responsible for ensuring that the company meets its long and short terms aims and the day to day operations run smoothly. The manager has delegated authority within terms of delegation approved by the trustees, for operational matters including finance and employment.

There is clear division of responsibility at the company with the Board retaining control over major decisions. The board of directors retain overall responsibility for the strategic development of the company in close liaison with the executive officers.

#### **Financial Review**

Against the backdrop of limited resources and insecurities over funding, it has continued to be difficult to plan or develop services. Nevertheless, the company with the aid of sound financial management and the support of both its staff and volunteers generated a satisfactory financial outcome.

The results for the financial year are set out on page 11 and additional notes are provided showing income and expenditure in greater detail.

#### **Results and Dividends**

At the end of the financial year the company had gross assets of €106,606 (2023 - €49,040) and gross liabilities of €71,489 (2023 - €13,923). The net assets of the company have decreased by €0.

## **Finglas Cabra Drugs and Alcohol Task Force CLG DIRECTORS' ANNUAL REPORT**

for the financial year ended 31 December 2024

### **Reserves Position and Policy**

In line with best practice in accounting and reporting, the Board of Directors have examined the company's requirements for reserves in light of the main risks to the organisation and also making allowance for the company's ability to respond quickly to any crisis situations that may arise without the need to wait for third party funding. This is in line with minimum recommended levels for the sector.

The reserves are needed to meet the working capital requirements of the company, to deal with emergency situations and to fund the expansion of the company's services going forward. The Board of Directors are confident that at this level they would be able to continue the current activities of the company in the event of a significant drop in funding while allowing time to raise other funding, while at the same time not holding excessive reserves that would unnecessarily reduce the amount spent on current activities. The Board have developed the reserves policy to assist in strategic planning, to inform a balanced budget process and to inform the risk management process by identifying and uncertainty in future income streams.

### **Principal Risks and Uncertainties**

The principal risk of the company is that funding would not be forthcoming. There are funding commitments from the HSE, City of Dublin Youth Service Board and Department of Health. As the company is dependent on the funding, the directors are monitoring this risk closely.

The company mitigates these risks by:

- Monitoring the level of activity, preparing and monitoring budgets, targets and projections. The company has a policy of maintaining adequate cash reserves;
- Closely monitoring emerging changes to regulations and legislation on an ongoing basis.

Internal control risks are minimised by the implementation of procedures for authorisation of all transactions and projects. Procedures are in place to ensure compliance with health and safety of staff, volunteers, clients and visitors.

### **Reputational risk**

In common with many companies, the company's principal risk is reputational damage. Reputation damage could be caused by an event outside the company's control. In order to mitigate this risk, the company continues to adopt best practices.

The company plans to continue to apply for funding from the state in order to carry on the services they provide. Each year they apply for funding through different sources. This funding is required in order for the company to maintain its services and cover the costs of these services. There are no other future developments to note.

### **Directors and Secretary**

The directors who served throughout the financial year, except as noted, were as follows:

Declan Meenagh

Cora Rafter

Martin Hoey (Appointed 28 March 2024)

Rachel Kelly (Resigned 28 March 2024)

In accordance with the Constitution, the directors retire by rotation and, being eligible, offer themselves for re-election.

The secretary who served throughout the financial year was Lorna Regan.

### **Compliance with Sector-Wide Legislation and Standards**

The company engages pro-actively with legislation, standards and codes which are developed for the sector. Finglas Cabra Drugs and Alcohol Task Force CLG subscribes to and is compliant with the following:

- The Companies Act 2014
- The Charities SORP (FRS 102)

### **The Auditors**


Donal Ryan & Associates resigned as auditors during the financial year and the directors appointed KSi Faulkner Orr Limited, to fill the vacancy.


**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**DIRECTORS' ANNUAL REPORT**  
for the financial year ended 31 December 2024

**Accounting Records**

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at 27 Annamoe Terrace, Cabra, Dublin 7.

Approved by the Board of Directors on 29/9/25 and signed on its behalf by:

  
\_\_\_\_\_  
Cora Rafter  
Director

  
\_\_\_\_\_  
Martin Hoey  
Director

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**DIRECTORS' RESPONSIBILITIES STATEMENT**  
for the financial year ended 31 December 2024

The directors are responsible for preparing the Directors' Annual Report and Financial Statements in accordance with the Companies Act 2014 and applicable regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the net income or expenditure of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in operation.


The directors confirm that they have complied with the above requirements in preparing the financial statements.


The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and net income or expenditure of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and the Directors' Annual Report comply with Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the directors are aware:

- there is no relevant audit information (information needed by the company's auditor in connection with preparing the auditor's report) of which the company's auditor is unaware, and
- the directors have taken all the steps that they ought to have taken as directors in order to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

Approved by the Board of Directors on 29/9/25 and signed on its behalf by:

  
Cora Rafter  
Director

  
Martin Hoey  
Director

# INDEPENDENT AUDITOR'S REPORT CLG

## to the Members of Finglas Cabra Drugs and Alcohol Task Force

### Report on the audit of the financial statements

#### Opinion

We have audited the company financial statements of Finglas Cabra Drugs and Alcohol Task Force CLG ('the Company') for the financial year ended 31 December 2024 which comprise the Statement of Financial Activities (incorporating an Income and Expenditure Account), the Balance Sheet and the notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with FRS 102.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the Company as at 31 December 2024 and of its surplus for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

#### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described below in the Auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

#### Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

#### Opinions on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Annual Report is consistent with the financial statements;
- the Directors' Annual Report has been prepared in accordance with the Companies Act 2014; and

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

## INDEPENDENT AUDITOR'S REPORT CLG to the Members of Finglas Cabra Drugs and Alcohol Task Force

### Respective responsibilities

#### Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement set out on page 7, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless they either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

#### Further information regarding the scope of our responsibilities as auditor

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Emma Delaney  
for and on behalf of  
KSI FAULKNER ORR LIMITED  
10 Lower Mount Street  
Dublin 2  
Ireland




**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**STATEMENT OF FINANCIAL ACTIVITIES**

(Incorporating an Income and Expenditure Account)  
 for the financial year ended 31 December 2024

	Notes	Restricted Funds 2024	Total Funds 2024	Restricted Funds 2023	Total Funds 2023
		€	€	€	€
<b>Income</b>					
Activities for generating funds	3.1	544,851	544,851	531,873	531,873
<b>Expenditure</b>					
Activities for generating funds	4.1	544,851	544,851	559,636	559,636
<b>Net income/(expenditure)</b>					
Transfers between funds		-	-	-	-
<b>Net movement in funds for the financial year</b>		-	-	(27,763)	(27,763)
<b>Reconciliation of funds:</b>					
Total funds beginning of the year	12	35,117	35,117	62,880	62,880
<b>Total funds at the end of the year</b>		<u>35,117</u>	<u>35,117</u>	<u>35,117</u>	<u>35,117</u>

The Statement of Financial Activities includes all gains and losses recognised in the financial year.

Approved by the Board of Directors and authorised for issue on 29/9/25 and signed on its behalf by

  
 Cora Rafter  
 Director


  
 Martin Hoey  
 Director

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**BALANCE SHEET**  
as at 31 December 2024

	Notes	2024	2023
		€	€
<b>Fixed Assets</b>			
Tangible assets	7	<u>7,204</u>	-
<b>Current Assets</b>			
Debtors	8	7,034	2,000
Cash at bank and in hand		<u>92,368</u>	<u>47,040</u>
		<u>99,402</u>	<u>49,040</u>
Creditors: Amounts falling due within one year	9	<u>(71,489)</u>	<u>(13,923)</u>
<b>Net Current Assets</b>		<u>27,913</u>	<u>35,117</u>
<b>Total Assets less Current Liabilities</b>		<u>35,117</u>	<u>35,117</u>
<b>Funds</b>			
Restricted trust funds		<u>35,117</u>	<u>35,117</u>
<b>Total funds</b>	12	<u>35,117</u>	<u>35,117</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

Approved by the Board of Directors and authorised for issue on 29/9/25 and signed on its behalf by

  
Cora Rafter  
Director

  
Martin Hoey  
Director

# **Finglas Cabra Drugs and Alcohol Task Force CLG**

## **NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 December 2024

### **1. GENERAL INFORMATION**

Finglas Cabra Drugs and Alcohol Task Force CLG is a company limited by shares incorporated in Ireland. The registered office of the company is 27 Annamoe Terrace, Cabra, Dublin 7, Ireland which is also the principal place of business of the company. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### **2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### **Statement of compliance**

The financial statements of the company for the financial year ended 31 December 2024 have been prepared on the going concern basis and in accordance with the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland FRS 102", applying Section 1A of that Standard.

#### **Fund accounting**

The following are the categories of funds maintained:

##### **Restricted funds**

Restricted funds represent income received which can only be used for particular purposes, as specified by the donors. Such purposes are within the overall objectives of the company.

##### **Unrestricted funds**

Unrestricted funds consist of General and Designated funds.

- General funds represent amounts which are expendable at the discretion of the board, in furtherance of the objectives of the company.
- Designated funds comprise unrestricted funds that the board has, at its discretion, set aside for particular purposes. These designations have an administrative purpose only, and do not legally restrict the board's discretion to apply the fund.

#### **Income**

Income is recognised by inclusion in the Statement of Financial Activities only when the company is legally entitled to the income, performance conditions attached to the item(s) of income have been met, the amounts involved can be measured with sufficient reliability and it is probable that the income will be received by the company.

#### **Income from charitable activities**

Income from charitable activities include income earned from the supply of services under contractual arrangements and from performance related grants which have conditions that specify the provision of particular services to be provided by the company. Income from government and other co-funders is recognised when the company is legally entitled to the income because it is fulfilling the conditions contained in the related funding agreements. Where a grant is received in advance, its recognition is deferred and included in creditors. Where entitlement occurs before income is received, it is accrued in debtors.

Grants from governments and other co-funders typically include one of the following types of conditions:

- Performance based conditions: whereby the company is contractually entitled to funding only to the extent that the core objectives of the grant agreement are achieved. Where the company is meeting the core objectives of a grant agreement, it recognises the related expenditure, to the extent that it is reimbursable by the donor, as income.

- Time based conditions: whereby the company is contractually entitled to funding on the condition that it is utilised in a particular period. In these cases the company recognises the income to the extent it is utilised within the period specified in the agreement.

In the absence of such conditions, assuming that receipt is probable and the amount can be reliably measured, grant income is recognised once the company is notified of entitlement.

Grants received towards capital expenditure are credited to the Statement of Financial Activities when received or receivable, whichever is earlier.

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 December 2024

**Expenditure**

Expenditure is analysed between costs of charitable activities and raising funds. The costs of each activity are separately accumulated and disclosed, and analysed according to their major components. Expenditure is recognised when a legal or constructive obligation exists as a result of a past event, a transfer of economic benefits is required in settlement and the amount of the obligation can be reliably measured. Support costs are those functions that assist the work of the company but cannot be attributed to one activity. Such costs are allocated to activities in proportion to staff time spent or other suitable measure for each activity.

**Employee Benefits**

The costs of short-term employee benefits are recognised as a liability and an expense.

**Tangible fixed assets and depreciation**

Tangible fixed assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible fixed assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment - 20% Straight line

**Debtors**

Debtors are recognised at the settlement amount due after any discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. Income recognised by the company from government agencies and other co-funders, but not yet received at financial year end, is included in debtors.

**Creditors**

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

**Cash at bank and in hand**

Cash at bank and in hand comprises cash on deposit at banks requiring less than three months notice of withdrawal.

**Taxation and deferred taxation**

No current or deferred taxation arises as the company has been granted charitable exemption. Irrecoverable valued added tax is expensed as incurred.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

3.	INCOME ACTIVITIES FOR GENERATING FUNDS	Unrestricted	Restricted	Total Funds		Total Funds 2023
				2024		
		Funds €	Funds €	€	€	€
	City of Dublin Youth Service Board	-	169,805	169,805	155,715	
	Department of Justice	-	88,932	88,932	94,451	
	Health Service Executive	-	285,843	285,843	281,707	
	Dublin Northwest Partnership	-	271	271	-	
		<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
		-	544,851	544,851	531,873	
		<hr/>	<hr/>	<hr/>	<hr/>	<hr/>

continued

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 December 2024

**4. EXPENDITURE**

4.1	ACTIVITIES FOR GENERATING FUNDS	Direct	Other	Support	2024	2023
		Costs €	Costs €	Costs €	€	€
	Support Costs	-	-	86,574	86,574	88,793
	Staff Costs	258,417	-	-	258,417	254,252
	Funding Programmes	193,344	-	-	193,344	210,806
	Governance Costs	-	-	6,516	6,516	5,785
		<u>451,761</u>	<u>-</u>	<u>93,090</u>	<u>544,851</u>	<u>559,636</u>

**4.2 SUPPORT COSTS**

		Cost of Generating Funds	2024	2023
		€	€	€
	Computer & IT costs	12,174	12,174	12,512
	Consultancy Fees	7,397	7,397	13,352
	Audit	6,516	6,516	5,785
	Office Set-up & Relocation costs	-	-	1,149
	Printing, postage and stationery	9,325	9,325	9,446
	Bank Charges	577	577	506
	General Expenses	10,281	10,281	3,880
	Motor expenses	624	624	-
	Other staff costs	9,640	9,640	6,505
	Light & Heat	4,169	4,169	4,201
	Rent payable	26,925	26,925	27,004
	Telephone & Internet	5,462	5,462	6,363
	Repairs & Maintenance	-	-	3,875
		<u>93,090</u>	<u>93,090</u>	<u>94,578</u>

**5. ANALYSIS OF SUPPORT COSTS**

		2024	2023
		€	€
	Computer & IT costs	12,174	12,512
	Consultancy Fees	7,397	13,352
	Audit	6,516	5,785
	Office Set-up & Relocation costs	-	1,149
	Printing, postage and stationery	9,325	9,446
	Bank Charges	577	506
	General Expenses	10,281	3,880
	Motor expenses	624	-
	Other staff costs	9,640	6,505
	Light & Heat	4,169	4,201
	Rent payable	26,925	27,004
	Telephone & Internet	5,462	6,363
	Repairs & Maintenance	-	3,875
		<u>93,090</u>	<u>94,578</u>

continued

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 December 2024

**6. EMPLOYEES AND REMUNERATION**

**Number of employees**

The average number of persons employed (including executive directors) during the financial year was as follows:

	2024 Number	2023 Number
Task Force	4	5
The staff costs comprise:		
Wages and salaries	232,410	246,558
Social security costs	26,007	-
Pension costs	9,465	7,694
	<hr/> <hr/> <hr/> <hr/> <hr/>	<hr/> <hr/> <hr/> <hr/> <hr/>
	267,882	254,252
	<hr/> <hr/> <hr/> <hr/> <hr/>	<hr/> <hr/> <hr/> <hr/> <hr/>

**7. TANGIBLE FIXED ASSETS**

	Fixtures, fittings and equipment €	Total €
<b>Cost</b>		
At 1 January 2024	6,484	6,484
Additions	7,204	7,204
	<hr/>	<hr/>
At 31 December 2024	13,688	13,688
<b>Depreciation</b>		
At 31 December 2024	6,484	6,484
<b>Net book value</b>		
At 31 December 2024	7,204	7,204
	<hr/> <hr/> <hr/>	<hr/> <hr/> <hr/>

**8. DEBTORS**

	2024 €	2023 €
Prepayments	2,000	2,000
Accrued Income	5,034	-
	<hr/>	<hr/>
	7,034	2,000
	<hr/> <hr/> <hr/>	<hr/> <hr/> <hr/>

**9. CREDITORS**

	2024 €	2023 €
<b>Amounts falling due within one year</b>		
Taxation and social security costs	7,489	-
Other creditors	700	-
Accruals	16,007	13,923
Deferred Income	47,293	-
	<hr/>	<hr/>
	71,489	13,923
	<hr/> <hr/> <hr/> <hr/> <hr/>	<hr/> <hr/> <hr/> <hr/> <hr/>

continued

**Finglas Cabra Drugs and Alcohol Task Force CLG  
NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 December 2024

**10. STATE FUNDING**

<b>Agency</b>	<b>Department of Health</b>
Sponsoring Government Department	Department of Health
Grant Programme	Family Support Worker
Term	January to December 2024
Total grant awarded	€75,811
Reflected in 2024	€78,949
Grant amounts deferred or (due) at financial year end	(€3,138)
Capital grant	No
Restriction on use	Restricted
<b>Agency</b>	<b>Department of Health</b>
Sponsoring Government Department	Department of Health
Grant Programme	Family Health Worker
Term	January to December 2024
Total grant awarded	€62,387
Reflected in 2024	€64,947
Grant amounts deferred or (due) at financial year end	(€2,560)
Capital grant	No
Restriction on use	Restricted
<b>Agency</b>	<b>Department of Health</b>
Sponsoring Government Department	Department of Health and Dublin Northwest Partnership FC2-7 Health Promotion respectively
Grant Programme	FC2-7 Health Promotion
Term	January to December 2024
Total grant awarded	€23,496 and €271 respectively
Reflected in 2024	€22,746 and €271 respectively
Grant amounts deferred or (due) at financial year end	€750
Capital grant	No
Restriction on use	Restricted

continued

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 December 2024

<b>Agency</b>	<b>Department of Health</b>
Sponsoring Government Department	Department of Health
Grant Programme	FC2-5 Progression Fund
Term	January to December 2024
Total grant awarded	€12,330
Reflected in 2024	€9,054
Grant amounts deferred or (due) at financial year end	€3,276
Capital grant	No
Restriction on use	Restricted
<b>Agency</b>	<b>Department of Health</b>
Sponsoring Government Department	Department of Health
Grant Programme	FC2-12 Admin Worker
Term	January to December 2024
Total grant awarded	€66,257
Reflected in 2024	€48,495
Grant amounts deferred or (due) at financial year end	€17,762
Capital grant	No
Restriction on use	Restricted
<b>Agency</b>	<b>Department of Health</b>
Sponsoring Government Department	Department of Health
Grant Programme	FC-16 Community Response Fund
Term	January to December 2024
Total grant awarded	€17,331
Reflected in 2024	€14,133
Grant amounts deferred or (due) at financial year end	€3,198
Capital grant	No
Restriction on use	Restricted

continued

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 December 2024

<b>Agency</b>	<b>Department of Health</b>
Sponsoring Government Department	Department of Health
Grant Programme	Admin Premises
Term	January to December 2024
Total grant awarded	€35,503
Reflected in 2024	€33,958
Grant amounts deferred or (due) at financial year end	€1,545
Capital grant	No
Restriction on use	Restricted
<b>Agency</b>	<b>Department of Health</b>
Sponsoring Government Department	Department of Health
Grant Programme	Admin
Term	January to December 2024
Total grant awarded	€10,000
Reflected in 2024	€4,564
Grant amounts deferred or (due) at financial year end	€5,436
Capital grant	No
Restriction on use	Restricted
<b>Agency</b>	<b>Department of Health</b>
Sponsoring Government Department	Department of Health
Grant Programme	Additional Funding
Term	January to December 2024
Total grant awarded	€21,637
Reflected in 2024	€8,997
Grant amounts deferred or (due) at financial year end	€12,641
Capital grant	No
Restriction on use	Restricted

continued

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 December 2024

<b>Agency</b>	<b>City of Dublin ETB/ City of Dublin Youth Services</b>
Sponsoring Government Department	Department of Children Equality Disability Integration & Youth (DCEDIY), Department of Health and Department of Education
Grant Programme	FC2-11
Term	January to December 2024
Total grant awarded	€56,532
Reflected in 2024	€58,099
Grant amounts deferred or (due) at financial year end	(€1,567)
Capital grant	No
Restriction on use	Restricted
<b>Agency</b>	<b>City of Dublin ETB/ City of Dublin Youth Services</b>
Sponsoring Government Department	Department of Children Equality Disability Integration & Youth (DCEDIY), Department of Health and Department of Education
Grant Programme	FC2-8A
Term	January to December 2024
Total grant awarded	€98,708
Reflected in 2024	€99,174
Grant amounts deferred or (due) at financial year end	(€466)
Capital grant	No
Restriction on use	Restricted
<b>Agency</b>	<b>City of Dublin ETB/ City of Dublin Youth Services</b>
Sponsoring Government Department	Department of Children Equality Disability Integration & Youth (DCEDIY), Department of Health and Department of Education
Grant Programme	FC2-B2
Term	January to December 2024
Total grant awarded	€9,556
Reflected in 2024	€12,532
Grant amounts deferred or (due) at financial year end	(€2,976)
Capital grant	No
Restriction on use	Restricted

continued

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 December 2024

Agency	Department of Justice
Sponsoring Government Department	Department of Justice
Grant Programme	Finglas Safety Forum
Term	January to December 2024
Total grant awarded	€97,290
Reflected in 2024	€88,932
Grant amounts deferred or (due) at financial year end	€8,358
Capital grant	No
Restriction on use	Restricted

**11. RESERVES**

	2024 €	2023 €
At the beginning of the year	35,117	62,880
Surplus/(Deficit) for the financial year	-	(27,763)
<b>At the end of the year</b>	<b>35,117</b>	<b>35,117</b>

**12. FUNDS**

	At 1 January 2023	62,880	62,880
Movement during the financial year	(27,763)	(27,763)	(27,763)
<b>At 31 December 2023</b>	<b>35,117</b>	<b>35,117</b>	<b>35,117</b>
<b>At 31 December 2024</b>	<b>35,117</b>	<b>35,117</b>	<b>35,117</b>

**12.1 ANALYSIS OF MOVEMENTS ON FUNDS**

	Balance 1 January 2024 €	Income €	Expenditure €	Transfers between funds €	Balance 31 December 2024 €
<b>Restricted funds</b>					
Restricted	35,117	544,851	544,851	-	35,117
<b>Total funds</b>	<b>35,117</b>	<b>544,851</b>	<b>544,851</b>	<b>-</b>	<b>35,117</b>

**12.2 ANALYSIS OF NET ASSETS BY FUND**

	Fixed assets - company use €	Current assets €	Current liabilities €	Total €
<b>Restricted trust funds</b>				
	7,204	99,402	(71,489)	35,117
	<b>7,204</b>	<b>99,402</b>	<b>(71,489)</b>	<b>35,117</b>

continued

**Finglas Cabra Drugs and Alcohol Task Force CLG**  
**NOTES TO THE FINANCIAL STATEMENTS**  
for the financial year ended 31 December 2024

**13. POST-BALANCE SHEET EVENTS**

There have been no significant events affecting the Company since the financial year-end.